CytoDyn (OTCMKTS:CYDY) Stock Price Crosses Below 50-Day Moving Average – What’s Next?

CytoDyn Inc. (OTCMKTS:CYDY) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.26 and traded as low as $0.2231. CytoDyn shares last traded at $0.2310, with a volume of 2,076,821 shares changing hands.

CytoDyn Price Performance

The company has a 50 day simple moving average of $0.26 and a 200-day simple moving average of $0.28. The stock has a market capitalization of $301.81 million, a P/E ratio of -7.85 and a beta of 1.14.

CytoDyn (OTCMKTS:CYDY) last announced its quarterly earnings data on Friday, January 9th. The biotechnology company reported ($0.02) earnings per share for the quarter.

About CytoDyn

CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.

In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.